# Special Issue

## Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Cancer Therapy

### Message from the Guest Editor

Peritoneal metastases (PMs) are common in the advanced stages of many intra-abdominal malignancies. Unfortunately, treatment options for unresectable PMs are limited, and the standard treatment is palliative systemic chemotherapy, with unsatisfactory results. PIPAC is an innovative treatment modality for unresectable peritoneal metastasis ensuring better distribution of the aerosolchemotherapy into the abdominal cavity and deeper tissues and nodules drug penetration. Since its first description in 2011. PIPAC has proven to be a feasible and safe procedure. Due to its mini-invasive nature and safe profile, it seems a promising tool for implementing the comprehensive treatment of patients with peritoneal metastasis. In this Special Issue, we aim to emphasize patient selection criteria, the treatment response assessment, the efficacy outcomes, the economic costs of the procedure, the pharmacokinetic results of the aerosol chemotherapy, and the emerging topic of PIPAC as neoadjuvant treatment. Original research articles and reviews are welcome. We look forward to receiving your contributions.

### **Guest Editor**

Dr. Andrea Di Giorgio

Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy

### Deadline for manuscript submissions

closed (31 July 2025)



### **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/208802

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

#### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

